Search

Displaying results 1641 - 1650 of 8195 in total
  1. Drug

    Pf-04531083

    go.drugbank.com/drugs/DB12468
    Investigational

    Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.

  2. Drug

    PF-03654764

    go.drugbank.com/drugs/DB12360
    Investigational

    PF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis.

  3. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  4. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). … [L6694] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: 11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE, 5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-
  5. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    It may be used alone or in combination with other drugs to manage hypertension[L7219] and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such

    Mixtures: CORBIS® D, BISOPROLOL DURA P 5/12.5MGCategories: P-glycoprotein inhibitors, P-glycoprotein substrates
  6. Drug

    Upleganan

    go.drugbank.com/drugs/DB21618
    Investigational

    Upleganan has a monoisotopic molecular weight of 1143.6 Da. … Upleganan is under investigation in clinical trial NCT04865393 (Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function).

  7. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.

  8. Drug

    PD-217014

    go.drugbank.com/drugs/DB12493
    Investigational

    PD-217,014 has been used in trials studying the treatment of Pain and Irritable Bowel Syndrome.

  9. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

  10. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality. … [L30260,L30275] Due to potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With